Showing results (601-610 of 1,177) with videos related to
Sort By:
Pageof 118
Applied Health Economics and Health Policy|June 11, 2016
A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol DependencePhilippe Laramée, Aurélie Millier, Nora Rahhali, et al.Applied Health Economics and Health Policy|October 17, 2013
Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder surveyDavid Tordrup, Aris Angelis, Panos KanavosApplied Health Economics and Health Policy|March 29, 2012
Cost effectiveness of prostacyclins in pulmonary arterial hypertensionAntonio Roman, Joan A Barberà, Pilar Escribano, et al.Applied Health Economics and Health Policy|March 30, 2016
Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in GermanyI Aumann, M Treskova, N Hagemann, et al.Applied Health Economics and Health Policy|December 10, 2015
A Scoping Review of Healthcare Costs for Patients with Cystic FibrosisIlene L Hollin, Karen A RobinsonApplied Health Economics and Health Policy|July 17, 2022
Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in AustraliaSameera Senanayake, Helen Healy, Steven M McPhail, et al.Applied Health Economics and Health Policy|July 17, 2022
Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive CancersRenée E Michels, Carlos H Arteaga, Michel L Peters, et al.Applied Health Economics and Health Policy|June 25, 2018
Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled DiabetesMegha Bansal, Mona Shah, Brian Reilly, et al.Applied Health Economics and Health Policy|June 21, 2018
Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in NorwayFredrik Salvesen Haukaas, Audun Ohna, Tania KrivasiApplied Health Economics and Health Policy|September 29, 2019
Estimating Attribute-Specific Willingness-to-Pay Values from a Health Care Contingent Valuation Study: A Best-Worst Choice ApproachIvan Sever, Miroslav Verbič, Eva Klaric SeverPageof 118